General description
This orthogonally-protected ornithine derivative is based on the hindered Dde variant ivDde. The side-chain ivDde group is considerably more stable to piperidine than Dde and is less prone to migrate from protected to unprotected side-chains [1]. When removing ivDde in the presence of allyl-based protecting groups, allyl alcohol should be included in the deprotection solution to prevent reduction of the allyl group [2].See references [3,4] for applications.
Associated Protocols and Technical Articles
Cleavage and Deprotection Protocols for Fmoc SPPS
Literature references
[1] S. R. Chhabra, et al. (1998) Tetrahedron Lett., 39, 1603.
[2] B. Rohwedder, et al. (1998) Tetrahedron Lett., 39, 1175.
[3] V. Wittmann & S. Seeberger (2000) Angew. Chem. Int. Ed. Engl., 39, 4348.
[4] S. M. Dankwardt, et al. (2001) Bioorg. Med. Chem. Lett., 11, 2085.
Linkage
Replaces: 04-12-1203
Analysis Note
Color (visual): white to slight yellow to beige
Appearance of substance (visual): powder
Identity (IR): passes test
Enantiomeric purity: ≥ 99.0 % (a/a)
Purity (TLC(011A)): ≥ 98 %
Purity (TLC(0811)): ≥ 98 %
Assay (HPLC, area%): ≥ 98.0 % (a/a)
Solubility (1 mmole in 2 ml DMF): clearly soluble
Assay (acidimetric): ≥ 85.0 %
Water (K. F.): ≤ 1.50 %
To see the solvent systems used for TLC of Novabiochem® products please click here.
Legal Information
Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51442002
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 8520880025